Login / Signup

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.

Fei MaMin YanWei LiQuchang OuyangZhongsheng TongYuee TengYongsheng WangShusen WangCuizhi GengTing LuoJincai ZhongQingyuan ZhangQiang LiuXiaohua ZengTao SunQinguo MoHu LiuYing ChengJing ChengXiaojia WangJianyun NieJin YangXinhong WuXinshuai WangHuiping LiChangsheng YeFangli DongShuchao WuXiaoyu ZhuBinghe Xunull null
Published in: BMJ (Clinical research ed.) (2023)
ClinicalTrials.gov NCT03863223.
Keyphrases
  • metastatic breast cancer
  • double blind
  • placebo controlled
  • clinical trial
  • phase iii
  • study protocol
  • phase ii
  • open label